Torigen Pharmaceuticals and Veterinary Management Groups Enter into Preferred Partner Agreement
Agreement provides member clinics and their patients with access to innovative companion animal cancer therapy
FARMINGTON, Conn., April 13, 2023 /PRNewswire-PRWeb/ -- Torigen Pharmaceuticals, Inc (Farmington, CT), an animal health biologics company, today announced it has entered into a Preferred Partner Agreement with Veterinary Management Groups (VMG) to provide their more than 2,000 member clinics with access to Torigen's experimental autologous prescription products and services. This agreement will further expand Torigen's ability to deliver innovative companion animal cancer treatments to an even greater patient population.
Torigen offers an experimental autologous cancer immunotherapy created from a surgically resected portion of tumor tissue that can be administered by both General Practitioners and Veterinary Oncologists. The combination of Torigen's innovative products and VMG's member organizations will allow more clinicians to be part of the veterinary oncology solution for a cancer diagnosis by providing alternative treatment options.
"We are excited by our agreement with Veterinary Management Groups and the opportunity to reach their more than 2,000 clinics," says Ashley Kalinauskas, CEO and Co-Founder of Torigen Pharmaceuticals. "This partnership will allow Torigen to provide even more practitioners with innovative immuno-therapeutics and access to our diagnostic partnerships when treating companion animal cancer patients."
Every year, nearly ten million companion animals are diagnosed with cancer and of those, only 1 in 10 pet parents seek a consultation with a veterinary oncologist after receiving a cancer diagnosis from their family veterinarian. This partnership will make cancer treatments for tumor-based cancers more readily available to pet parents across the United States. Torigen's mission is to empower veterinarians to be part of the solution through partnership and collaboration early in the diagnosis process. This is achieved by harnessing the power of the immune system to advance veterinary medicine.
"This exciting partnership combines Torigen's innovative products with VMG's member network allowing more clinicians to access veterinary oncology solutions and cancer treatment options, delivering more care to patients in need," said Matthew Salois, President of VMG.
About Torigen's Autologous Cancer Vaccine:
Torigen produces a personalized autologous prescription product for dogs, cats, and horses that uses the animal's own tumor cells to create immunotherapy from a surgically resected portion of a tumor that can be used alone or in combination with chemotherapy and radiation. Torigen's autologous prescription product is an experimental product regulated by the USDA Center of Veterinary Biologics under 9 CFR 103.3.
Torigen's autologous prescription product is an active immunotherapy consisting of cells harvested from the patient's own tumor. This whole-cell tumor vaccine is generated by a patented method to preserve cellular material and tumor- associated antigens and then mixed with immune-stimulating adjuvants. The objective is to increase the activation of tumor-specific T-cells resulting in an enhanced ability of the pet's immune system to destroy cancer cells, stop or slow the growth of cancer cells, or delay cancer metastasis.
About Torigen Pharmaceuticals Inc:
Torigen is transforming pet cancer treatment by harnessing the pet's immune system to create personalized cancer immunotherapies, making pet cancer treatment more accessible and more affordable. Torigen recognizes the instrumental role pets play in our families and is determined to extend the lives of companion animals despite a cancer diagnosis. With over 50% of all dogs over the age of 10 dying from cancer, Torigen is dedicated to providing affordable and effective cancer care solutions for all companion animals. Torigen is a spin-out from the University of Notre Dame and backed by Werth Family Investment Associates, Connecticut Innovations, Emerald Development Managers, Ironwood Capital, Advantage Capital, The University of Connecticut, The University of Notre Dame, SoGal Ventures, Gaingels, and other prominent investors. For more information visit http://www.torigen.com.
About VMG:
Veterinary Management Groups provides structure that enables practice owners to benefit from each other's wisdom, ideas and experiences through a peer study group experience. Each VMG is made up of 16-22 veterinary practice owners and meets biannually to share information, data, and management experiences. Mutual support and motivation help VMG members attain higher levels of success as practice administrators and leaders. More information about Veterinary Management Groups, including membership and contact details, may be found at: http://www.myvmg.com.
Media Contact
John Kallassy, Torigen, 860-519-9956, [email protected]
SOURCE Torigen
Share this article